"Patrick Neven, MD, PhD Universitaire Ziekenhuizen Leuven, Belgium 5Live #ASCO20"
4:58
Key Insights on MONARCH 2: subgroup analysis of pts receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced BC
Key Insights on MONARCH 2: subgroup analysis of pts receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced BC
Breast Cancer Similar Videos
-
Podium to Practice: Recent Updates on the Treatment of Breast Cancer from the 2021 San Antonio Breast Cancer Annual Meeting_Sara Hurvitz, MD, FACP_Sara Tolaney, MD, MPH
38:09
-
Sara Hurvitz, MD; University of California Los Angeles; 5Live #SABCS21
5:47
Key insights from the 2021 Annual Breast meeting in San Antonio
-
Harnessing the Power of Antibody-Drug Conjugates for the Treatment of Hematologic and Solid Cancer: Leveraging Antibody-Drug Conjugates in Breast Cancer Care_Hope Rugo, MD, FASCO
53:15